---
schema_version: "secwatch.filing_event.v1"
accession: "0000313143-23-000048"
form_type: "8-K"
ticker: "HAE"
cik: "0000313143"
company_name: "HAEMONETICS CORP"
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:57:10.145841+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Haemonetics to acquire OpSens for CAD $2.90/share in cash, expected close by March 31, 2024

## Summary
- Haemonetics (HAE) will pay CAD $2.90 per share for all OpSens common shares via a plan of arrangement under Québec law.
- Closing conditions include 2/3 shareholder vote, HSR and Investment Canada approvals, court order, and no material adverse effect.
- OpSens directors and officers owning ~4.75% of shares have agreed to vote in favor via voting agreements.
- If OpSens terminates for a superior proposal or changes recommendation, it pays Haemonetics a CAD $12.075M termination fee.
- The transaction must close by March 31, 2024, with an automatic 75-day extension if regulatory approvals are not yet obtained.

## SEC filing metadata
- accession: 0000313143-23-000048
- form_type: 8-K
- ticker: HAE
- cik: 0000313143
- company_name: HAEMONETICS CORP
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/0000313143-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/hae-20231010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000313143-23-000048
- JSON: https://secwatch.observer/filing/0000313143-23-000048.json
- Plain text: https://secwatch.observer/filing/0000313143-23-000048.txt

## Key facts
- Material Agreements
  HAEMONETICS CORP entered into Arrangement Agreement with OpSens Inc., 9500-7704 Québec Inc. valued at CAD $2.90 (effective 2023-10-10).
  - Action: entry
  - Agreement: merger
  - Counterparty: OpSens Inc., 9500-7704 Québec Inc.
  - Value: CAD $2.90
  - Effective: 2023-10-10
  source text: On October 10, 2023, Haemonetics Corporation, a Massachusetts corporation (“ Haemonetics ” or the “ Company ”), OpSens Inc., a corporation existing under the Business Corporations Act (Québec) (“ OpSens ”), and 9500-7704 Québec Inc., a corporation existing under the Business Corporations Act (Québec) and a wholly owned subsidiary of Haemonetics (the “ Purchaser ” and, together with Haemonetics, the “ Purchaser Parties ”), entered into an Arrangement Agreement (the “ Arrangement Agreement ”), pursuant to which, among other things, the Purchaser has agreed to acquire all of the issued and outstanding common shares of OpSens (the “ Arrangement ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/313143/000031314323000048/0000313143-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.